Новые возможности в лечении больных со стабильными проявлениями атеротромбоза

атеротромбоз, лечение, новые возможности, atherothrombosis, treatment, new possibilities

1. WHO. Cardiovascular diseases. WHO; 2016.

2. Rosamond W., Flegal К., Furie К. et al. Heart Disease and Stroke Statistics-2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcomittee. Circulation 2008; 117: e25 - e146.

3. Nichols M., Townsend N., Scarborough, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014; 35: 2950-2959.

4. Benjamin E.J. Blaha M.J., Chiuve S.E. et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135; e146 - e603.

5. Демография: Федеральная служба государственной статистики

6. Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367; 1747-1757.

7. Комаров А.Л., Панченко Е.П., Деев А.Д. и др. Течение перемежающейся хромоты и прогноз больных атеросклеротическим поражением артерий нижних конечностей. Анализ результатов проспективного наблюдения. Ангиология и сосудистая хирургия 2000; 2: 9-19

8. Dormandy J., Mahir H., Ascady G. et al. Fate of the patient with chronic leg ischemia. J. Cardiovasc Surg 1989; 30: 50-57.

9. Smith G.D., Shipley M.J. Intermittent claudication, heart disease risk factors, and mortality: The Whitehall Study. Circulation 1990; 82: 1925-1931.

10. Панченко Е.П. Результаты трехлетнего наблюдения за амбулаторными больными с клиническими проявлениями атеротромбоза (анализ российской популяции регистра REACH) Кардиология 2009; 10: 9-14

11. Ph. Gabriel Steg, MD; Deepak L. Bhatt, MD; Peter W. F. Wilson, MD; et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis JAMA 2007; 297: 1197-1206.

12. Borissoff J.I., Spronk H.M., Heeneman H.S., ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis'maze? Cardiovasc Res 2009; 82: 392-403.

13. Deepak L. Bhatt, M.D., Keith A.A. Fox, M.B., Ch.B. et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N. Engl J. Med 2006; 354: 1706-1717.

14. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl J. Med 2001; 345: 494-502.

15. Bhatt, M.D., Keith A.A. Fox, M.B., Ch.B. et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N. Engl J. Med 2006; 354: 1706-1717.

16. Stone G.W., Maehara A., Lansky A.J. et al. A prospective natural-history study of coronary atherosclerosis. N. Engl J. Med 2011; 364: 226-235.

17. Mauri L., D. Kereiakes, R. Yeh. et al. Twelve or 12 months of dual antiplatelet therapy after drug-eluting stents. N. Engl J. Med 2014; 371: 2155-2166.

18. Bonaca M., Bhatt D.,.Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl J. Med 2015; 372: 1791-800.

19. Merlini P.A., Bauer K.A., Oltrona L. et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.

20. Panchenko E., Dobrovolsky A., Davletov K. et аl. D-dimer and fibrinolytic system in patients with various degrees of atherosclerosis. Eur Heart J. 1995; 16: 38-42.

21. Комаров А.Л., Шахматова О.О., Илющенко Т.А. и др. Факторы, определяющие прогноз у больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология 2012; 1: 4-14

22. Rothberg M.B., Selestin C., Fiore L.D. et al. Warfarin plus aspirin after MI or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250.

23. Hansen M.L., Sorensen R., Clausen M.T. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.

24. Mega J., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 29-38.

25. Mega J., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl J. Med 2012; 366: 9-11.

26. Eikelboom J.W., Connolly S.J., Bosch J. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl J. Med 2017; Aug 27. doi: 10.1056/NEJMoa1709118